Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.80), $0.54 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $230.27 million versus the consensus estimate of $233.93 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.